

Indivumed, IMCB to build multiomics cancer database

06 July 2018 | News

This contributes to Indivumed's global cancer database solution IndivuType, funded by the European Investment Bank and private investors.



Indivumed GmbH and A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore have signed an agreement to perform proteomic and phosphoproteomic analysis of thousands of tissue samples from Indivumed's unique biobank.

This contributes to Indivumed's global cancer database solution IndivuType, funded by the European Investment Bank and private investors. IndivuType combines comprehensive cell biological information such as genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with extensive clinical information from thousands of patients.

A portal IT solution with a variety of cutting-edge bioinformatic and artificial intelligence tools enables cancer researchers and clinicians to comprehensively analyze and understand the complexity of the disease.